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Thirst is a common and burdensome symptom of chronic heart failure which adversely 
affects health related quality of life and compliance to self-care practices such as fluid 
restriction. Despite this, research on thirst remains scarce and there is no standard 
approach to identify patients with increased thirst and manage thirst in clinical practice. To 
date, previous studies have investigated various interventions to help alleviate thirst in 
chronic heart failure and other patient populations. While the other interventions such as 
artificial saliva showed differing results, chewing gum demonstrated promising outcomes in 
relieving thirst. Based on the comprehensive literature review and preliminary Bachelor 
Honours study, RELIEVE-CHF was developed. RELIEVE-CHF was a novel pilot intervention 
which sought to investigate the effect of chewing gum in the level of thirst of people with 
chronic heart failure in a single blind randomised controlled study.   
A total of 71 individuals with chronic heart failure, aged ≥ 18 years, on oral loop diuretics 
from the inpatient and outpatient clinic were enrolled in a two-arm trial. Participants were 
randomised to receive either chewing gum or no chewing gum for two weeks. The primary 
outcome of the study is the change in the level of thirst at Day 4. Secondary outcomes 
included changes in the level of thirst at Day 14, weight and health related quality of life.  
Participants’ level of thirst was measured using the Visual Analogue Scale (VAS) and the 
Numeric Rating Scale (NRS). The Kansas City Cardiomyopathy Questionnaire was used to 
assess health related quality of life. Participants were followed up at Day 28.  
This thesis presents the clinical trial methodology and analysis of 71 participants who 




principle. The results showed statistical significant improvements in the level of thirst of 
those in the intervention group compared to the control group at Day 4 (VAS: p=0.04 and 
NRS: p=0.019) and Day 14 (VAS: p=0.02 and NRS: p=0.021). There was no statistically 
significant difference observed between the intervention and control group in weight over 
the study period and health related quality of life at Day 28. The findings indicate that 
chewing gum provided relief from thirst but did not influence weight or health related 
quality of life during the study period. Although promising, these findings must be 
interpreted in light of the limitations encountered in this trial. Nonetheless, RELIEVE-CHF 
have provided additional data to inform future clinical intervention studies and insights into 
the challenge of implementing a non-traditional approach in relieving thirst in people with 
chronic heart failure.  
 
  
